Log In
Print
BCIQ
Print
Print this Print this
 

Mekinist, trametinib (GSK1120212)

Also known as: 1120212

  Manage Alerts
Collapse Summary General Information
Company Japan Tobacco Inc.
DescriptionSmall molecule inhibitor of MAP kinase kinase 1 (MAP2K1; MEK1) and MAP kinase kinase 2 (MAP2K2; MEK2)
Molecular Target MAP kinase kinase 1 (MAP2K1) (MEK1) ; MAP kinase kinase 2 (MAP2K2) (MEK2)
Mechanism of ActionKinase inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$16,000.0M

$14,500.0M

$1,500.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today